SCHEMBL3208972

SCHEMBL3208972

O=C(NCCO)c1ccc(-c2cccc3cc(Cc4cccc(C(F)(F)F)c4)sc23)nc1

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 20/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855306 0.97 GPR52 (0.69) GPR52
SCHEMBL3206560 0.89 GPR52 (0.73) GPR52
SCHEMBL3210137 0.88 GPR52 (0.78) GPR52
SCHEMBL7953999 0.88 GPR52 (0.64) GPR52
SCHEMBL3196520 0.88 GPR52 (0.86) GPR52
SCHEMBL3196429 0.87 GPR52 (0.67) GPR52
SCHEMBL3219563 0.87 GPR52 (0.55) GPR52
SCHEMBL3263212 0.86 GPR52 (0.69) GPR52
SCHEMBL3209653 0.86 GPR52 (0.62) GPR52
SCHEMBL3217375 0.85 GPR52 (0.70) GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.